Phase I first-in-human study to evaluate GSK’s OX40 agonist GSK3174998 as monotherapy and in combination with Merck’s anti-PD-1 therapy, KEYTRUDA® (pembrolizumab)     LONDON & KENILWORTH, N.J.–(BUSINESS WIRE)–GSK and Merck, known as MSD outside the US and Canada, today announced the initiation of a phase I clinical trial designed to evaluate GSK’s investigational immunotherapy GSK3174998 […]

Synta Pharmaceuticals Corp has decided to end a late-stage trial of its lung cancer treatment after an independent review said it proved ineffective, nearly halving its stock in extended trading on Tuesday. Lexington, Massachusetts-based Synta’s shares were down 46.6 percent at $1.09 after the bell. The late stage study aimed to see if a combination […]

Merck KGaA is betting on its oncology pipeline to revitalize the German drugmaker as it sees falling sales from its best-selling medicine, multiple sclerosis treatment Rebif. Luciano Rossetti, head of global research and development at Merck’s biopharma business Merck Serono, said the company is in a “rapid evolution,” with up to 80 percent of its […]

INDIANAPOLIS – Eli Lilly and Company (LLY) and Shanghai-based Innovent Biologics, Inc. have expanded their drug development collaboration to include three anti-PD-1 based bispecific antibodies for cancer treatments over the next decade, the company announced this morning.  The announcement expands on an existing deal between the two companies originally announced in March. The original deal to develop three cancer therapies could […]

AstraZeneca has temporarily halted two clinical trials combining experimental drugs to treat lung cancer, following reports of lung disease in some patients, the company said on Friday. The trials involve giving its drug AZD9291, which is currently awaiting regulatory approval, alongside the immune system-boosting medicine durvalumab, also known as MEDI4736, to treat patients with advanced […]

The U.S. Food and Drug Administration on Friday approved Merck & Co Inc’s immunotherapy, Keytruda, for patients with the most common form of lung cancer whose tumors produce a specific biological marker. The FDA approval for Keytruda in advanced non-small cell lung cancer is for patients whose tumors express PD-L1, a protein targeted by the […]

Study Evaluated Efficacy and Safety of ABP 215 Compared With Bevacizumab in Patients With Advanced Non-small Cell Lung Cancer Primary Efficacy Analysis Demonstrates Clinical Equivalence; Safety, Immunogenicity Comparable to Bevacizumab   THOUSAND OAKS, Calif. and DUBLIN, Sept. 23, 2015 /PRNewswire/ — Amgen (NASDAQ: AMGN) and Allergan plc. (NYSE: AGN) today announced a Phase 3 study […]

SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that in the large pivotal Phase II study, BIRCH, the investigational cancer immunotherapy atezolizumab (MPDL3280A; anti-PDL1) met its primary endpoint and shrank tumors (objective response rate; ORR) in people with locally advanced or metastatic non-small cell lung […]

Genentech (RHHBY)’s investigational cancer drug atezolizumab successfully shrank tumors in people with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose disease expressed PD-L1, the company announced this morning. Atezolizumab, MPDL3280A, is an investigational monoclonal antibody designed to interfere with a protein called PD-L1 (Programmed Death Ligand-1). Atezolizumab is designed to target PD-L1 expressed […]

Merck’s immune-boosting cancer drug, Keytruda, bested the standard of care in advanced melanoma, the deadly skin cancer, and showed promising results in non-small cell lung cancer. Based on these data, Merck says it has filed an application with the Food and Drug Administration for Keytruda to be used in non-small cell lung cancer, and will soon […]